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Background. Osteoporosis is an extrapulmonary eﬀect of chronic obstructive pulmonary disease (COPD). Diagnosis of
osteoporosis is based on BMD measured by DXA-scan. The best location for BMD measurement in COPD has not been
determined. Aim of this study was to assess whole-body BMD and BMD of the hip and lumbar spine (local DXA) in COPD
patients and compare the prevalence of osteoporosis at these locations. Methods. Whole body as well as local DXA-scan were made
in168COPDpatientsenteringpulmonaryrehabilitation.Patient-relevantcharacteristicswereassessed.Prevalenceofosteoporosis
was determined. Characteristics of patients without osteoporosis were compared to patients with osteoporosis on local DXA.
Results. A higher prevalence of osteoporosis was found using local DXA compared to whole-body DXA (39% versus 21%). One
quarterofpatientswithoutosteoporosisonwholebody-DXAdidhaveosteoporosisonlocalDXA.Signiﬁcantdiﬀerencesinpatient
characteristics between patients without osteoporosis based on both DXA measurements and patients with osteoporosis based on
local DXA only were found. Conclusions. DXA of the hip and lumbar spine should be made to assess bone mineral density in
COPD patients. The lowest T-score of these locations should be used to diagnose osteoporosis.
1.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by a progressive airﬂow obstruction [1]. In addition,
there are signiﬁcant extrapulmonary eﬀects, like osteoporo-
sis. Osteoporosis is a systemic skeletal disease characterized
byalowbonemineraldensity(BMD)andmicroarchitectural
changes in bones leading to an increased bone fragility and,
in turn, resulting in an increased fracture risk [2].
The prevalence of osteoporosis in COPD is higher than
in healthy age-matched control subjects [3]. Moreover,
COPD patients have a 60 to 70% higher risk of death
following hip fracture than people without COPD [4]. It is
therefore of high clinical importance to diagnose and treat
osteoporosis in COPD according to international guidelines
[2].
The gold standard for the diagnosis of osteoporosis
is dual-energy absorptiometry (DXA) [2]. Multiple sites
can be used to measure BMD by DXA. The sites most
frequentlyusedarethehip,thelumbarspine,forearmand/or
whole-body. Several studies investigated the best location
for DXA-scanning to diagnose osteoporosis [5–10]. DXA-
scanning of the hip and the lumbar spine resulted in a
higher prevalence of osteoporosis than whole-body DXA-
scanning in pre- and postmenopausal women [6]. Indeed,
theInternationalSocietyforClinicalDensitometryadvocates
to measure BMD of the lumbar spine and the hip and to
diagnose osteoporosis based on the lowest T-score of the
measured locations [11]. To date, a comparison of BMD of
various skeletal sites has not been performed in patients with
clinically stable COPD. Therefore, the aim of this study was
to compare the prevalence of osteoporosis using whole-body2 Journal of Osteoporosis
Table 1: Patients characteristics.
Total group (N = 168) Men (N = 103) Women (N = 65) P-value
Age, years 63.6±9.1 (39–85) 65.9±8.6 60.0±8.7 <.001
FEV1, %predicted 44.3±18.5 45.06±18.1 43.12±19.2 .0510
GOLD I, % 6.0 6.8 4.6
.402 GOLD II, % 24.6 24.3 26.2
GOLD III, % 26.3 30.1 20.0
GOLD IV, % 43.1 38.8 49.2
Arterial blood gas
pH 7.43±0.03 7.44±0.03 7.43±0.03 .078
PaCO2, kPa 5.4±0.8 5.4±0.9 5.6±0.7 .106
PaO2, kPa 9.5±1.4 9.5±1.5 9.4±1.3 .466
SO2,% 9 5 ±39 4 ±39 5 ±2 .536
Smoking
Ex-Smoker∗, % 66.7 71.8 58.5 .073
Pack Years 38.8±15.5 38.9±15.0 38.8±1603 .960
BMI, kg/m2 24.7±4.4 24.7±4.4 24.7±4.5 .960
Low, % 20.8 21.4 20.0
.561 Normal, % 30.4 33.0 26.2
High, % 38.1 34.0 44.6
Obese, % 10.7 11.7 9.2
FFMI, kg/m2 16.1±2.1 16.8±2.0 15.1±1.8 <.001
Normal/Low, % 58.9/41.1 61.2/38.8 55.4/44.6 .458
Whole body DXA
BMD, g/cm2 1.079±0.118 1.113±0.114 1.025±0.103 <.001
T-score −1.3±1.4 −1.3±1.4 −1.3±1.3 .762
Normal BMD, % 40.5 41.7 38.5 .075
Osteopenia, % 36.9 31.1 46.2 .217
Osteoporosis, % 22.6 27.2 15.4 .081
DXA hip
BMD, g/cm2 0.827±0.149 0.858±0.146 0.779±0.143 .001
T-score −1.7±1.1 −1.6±1.1 −1.9±1.0 .151
Normal BMD, % 22.6 25.2 18.5
.400 Osteopenia, % 52.4 53.4 52.3
Osteoporosis, % 25.0 21.4 29.2
DXA LS
BMD, g/cm2 1.065±0.215 1.088±0.211 1.027±0.218 .074
T-score −1.3±1.8 −1.2±1.8 −1.4±1.8 .471
Normal BMD, % 39.3 44.7 30.8 .198
Osteopenia, % 33.3 30.1 38.5
Osteoporosis, % 27.4 25.2 30.8
DXA hip and LS
Normal BMD, % 15.5 19.4 10.8
.175 Osteopenia, % 45.8 46.6 43.1
Osteoporosis, % 38.7 34.0 46.2
6MWD, m (n = 165) 420.61±135.66 454.41±132.57 368.62±124.28 <.001
Oral corticosteroids, % 17,9 18.4 16.9 .802
Daily dose#, mg 5.9±2.1 (2.5–10) 6.1±2.1 5.7±2.3 .653
Inhaled 85.7% 83.5 89.2 .301
corticosteroids, %
R e s u l t sa r ep r e s e n t e da sm e a n s± standard deviation, unless otherwise indicated.
∗Rest of the patients are current smokers.
#Only patients using oral corticosteroids on a daily base (n = 30).
Abbreviations:FEV1 =forcedexpiratoryvolumeintheﬁrstsecond;GOLD =GlobalStrategyfortheDiagnosis,ManagementandpreventionofCOPD;COPD
= chronic obstructive pulmonary disease; BMI = body mass index; FFMI = fat free mass index; DXA = dual energy absorptiometry; BMD = bone mineral
density; LS = lumbar spine; 6MWD = six minutes walking distance; m = meters; PaCO2 = arterial carbon dioxide tension; PaO2 = Arterial oxygen tension;
SO2 = Oxygen saturation.Journal of Osteoporosis 3
Table 2: Osteoporosis versus no osteoporosis based on local DXA
and whole body DXA.
Whole body DXA Local DXA
Osteoporosis No osteoporosis
Osteoporosis 33 5
No osteoporosis 32 98
Post Hoc test (McNemar): Relative risk 6.4; 95% conﬁdence interval 2.93–
32.06; P<. 0001. (Relativerisk: therisk of having osteoporosison local DXA
in case of a normal whole-body DXA is 6.4 times higher than the risk of
having osteoporosis on whole body DXA in case of a normal local DXA.)
Table 3: Osteoporosis versus no osteoporosis based on DXA of the
lumbar spine and of the hip.
DXA Hip DXA LS
Osteoporosis No osteoporosis
Osteoporosis 23 19
No osteoporosis 23 103
Abbreviations: LS = lumbar spine.
Post hoc test (McNemar): Relative risk 1.21; P = .644. (Relative risk: the risk
of having osteoporosis on lumbar spine DXA in case of a normal hip DXA
is 1.21 times higher than the risk of having osteoporosis on hip DXA in case
of a normal lumbar spine DXA.)
DXA-scanning versus local DXA-scanning (hip and lumbar
spine) in male and female COPD patients. To identify risk
factors for osteoporosis, patients without osteoporosis based
on both DXA measurements were compared to patients with
osteoporosis based on local DXA only.
2. Methods
The results of 168consecutive COPD patients between
November 2007 and May 2008 at CIRO, a centre of expertise
for chronic organ failure in Horn (the Netherlands), were
included in this retrospective study. All patients underwent
all the tests during a 3-day baseline assessment before enter-
ing a patient-tailored pulmonary rehabilitation program
[12].Therefore,ourmanuscriptdoesnotincludeastatement
of patient consent and the approval of Internal Review
Boards.
Medical history, current medication use, and smok-
ing status were assessed. Post-bronchodilator pulmonary
function tests were performed (Jaeger MASTERLABBODY,
VIASYS Healthcare) and COPD was diagnosed and clas-
siﬁed according to the GOLD guidelines [1]. Body mass
index (BMI) was deﬁned as low (<21kg/m2), normal
(21–25kg/m2), overweight (>25–30kg/m2), and obese
(>30kg/m2). Fat-free mass index (FFMI) was assessed by
bio-impedance analysis (BODYSTAT 1500 medical, single
frequency; Xitron Technologies) and classiﬁed as depleted
(men <16kg/m2 and women <15kg/m2)o rn o r m a l[ 13]. A
six-minute walking distance test was performed to estimate
functional exercise capacity [14]. Arterial blood gases were
collected to determine pH, arterial carbon dioxide tension
(PaCO2), and arterial oxygen tension (PaO2).
W h o l e - b o d yB M Da sw e l la sB M Da tt h ef e m u ra n dt h e
lumbar spine (L1–L4) were assessed for each patient using
a DXA-scan (Lunar Prodigy Ge-Lunar). Because the risk of
hip and vertebral fractures is similar in men and women for
any given BMD, we used the NHANES III data to calculate
T-scores for both men and women [15, 16]. For whole-
body DXA osteoporosis was deﬁned by a T-score < −2.35,
osteopenia: T-score between −2.35 and −0.9, and normal
BMD: T-score > −0.9 [17]. For local DXA, osteoporosis
was deﬁned by a T-score of ≤− 2.5, osteopenia as T-score
between −1a n d−2.5, and normal BMD: T-score > −1
[2]. To compare diﬀerent locations of DXA-scan, we divided
groups into osteoporosis and no osteoporosis (osteopenia
and normal BMD combined) because only patients with
osteoporosis need to be treated pharmacologically.
2.1. Statistical Analyses. Discrete variables were compared
with the Chi-square test and presented as percentages.
Continuous variables were compared with independent t-
test and presented as means ± standard deviation (SD).
Pearson correlation was used. To estimate the relative risk a
McNemars test was used. A P-value of <.05 was considered
signiﬁcant. All statistical analyses were performed using
Statistical Package for Social Sciences (SPSS) version 16.0.
3. Results
Mostly male patients with clinically stable, mild to very
severe COPD were studied. Based on whole-body DXA-scan
prevalence of osteoporosis was 22.6% versus 38.7% based
on hip and/or the lumbar spine DXA-scan (local DXA)
(Table 1).
Twenty-ﬁve percent of the 130 patients with a T-score
> −2.35 as determined by whole-body DXA did have
osteoporosis based on local DXA. In contrast, only 3.7% of
the 103 patients with a T-score > −2.5 as determined by
local DXA did have osteoporosis based on whole-body DXA
(Table 2). This diﬀerence in prevalence was highly signiﬁcant
(P<. 0001). The relative risk of having osteoporosis on local
DXA in case of no osteoporosis on whole-body DXA was 6.4
times higher than the risk of having osteoporosis on whole-
body DXA in caseof noosteoporosis onlocal DXA (Table 2).
Almost 16% of 122 patients with T-scores > −2.5 as
determined by DXA at the lumbar spine did have osteo-
porosis based on DXA at the hip. In addition, a little over
18% of 126 patients with T-scores > −2.5 based on hip
DXA-scanning did have osteoporosis on DXA-scan of the
lumbar spine (Table 3). This diﬀerence was not signiﬁcant
(P = .644).
Signiﬁcant diﬀerences were found in gender-
distribution, proportion of GOLD IV patients, arterial
blood gases, and functional exercise capacity between COPD
patients without osteoporosis on whole-body DXA as
well as local (hip and lumbar spine) DXA (group I) and
those without osteoporosis on whole body DXA and with
osteoporosis on local DXA (group II) (Table 4).4 Journal of Osteoporosis
Table 4: Diﬀerences between patients without osteoporosis and osteoporosis on local DXA.
Group I (N = 98) Group II (N = 32) P-value
Male/Female, % 64/36 38/62 .008
Age, years 64.0±9.2 61.7±9.2 .229
FEV1, % predicted 46.6±17.3 40.7±20.9 .110
GOLD I, % 5 6 .803
GOLD II, % 29 19 .272
GOLD III, % 31 16 .097
GOLD IV, % 36 59 .018
Arterial blood gas
pH 7.43±0.03 7.42±0.03 .267
PaCO2 (kPa) 5.38±0.72 5.71±0.85 .033
PaO2 (kPa) 9.62±1.28 9.00±1.51 .024
SO2 (%) 94.91±2.54 93.73±3.03 .032
BMI 25.88±3.93 25.11±4.03 .342
Low BMI, % 8 19 .093
Normal BMI, % 35 25 .309
High BMI, % 43 47 .691
Obese BMI, % 14 9 .474
6MWD, meters 443±128 354±146 .002
Group I = Patients without osteoporosis on total body DXA-scan and without osteoporosis on local DXA-scan.
Group II = Patients without osteoporosis on total body DXA-scan and with osteoporosis on local DXA-scan.
R e s u l t sa r ep r e s e n t e da sm e a n± standard deviation or as % of the group.
Abbreviations: FEV1 = forced vital capacity in the ﬁrst second; GOLD = Global Strategy for the Diagnosis, Management and prevention of COPD; COPD
= chronic obstructive pulmonary disease; PaCO2 = arterial blood carbon dioxide tension; PaO2 = arterial blood oxygen tension; SO2 = oxygen saturation in
arterial blood; BMI = body mass index. 6MWD = 6 minutes walking distance.
4. Discussion
Appreciatingthepossibleimpactofosteoporosisonfractures
andsurvivalinCOPD[4],itisclinicallyimportanttohavean
early and accurate diagnosis. In the present study a method-
speciﬁcdiﬀerenceindiagnosing osteoporosis hasbeenfound
in patients with COPD. Indeed, whole-body DXA-scanning
underestimates the prevalence of osteoporosis in COPD
(Table 1). This ﬁnding is in accordance with the ﬁndings in
pre- and postmenopausal women without COPD [6].
The prevalence of osteoporosis has been shown to diﬀer
when the same cut-oﬀ value for the T-score is used to deﬁne
osteoporosis [18, 19]. This leads to an over- or underestima-
tion of osteoporosis depending on the method used to asses
BMD. In order to compare whole-body DXA to local DXA,
we corrected for this diﬀerence in methodology by deﬁning
osteoporosis according to Boyanov [17] and the WHO [2],
respectively. In turn, a good sensitivity-to-speciﬁcity ratio in
the diagnosis of osteoporosis was obtained [17].
A possible explanation for the method-speciﬁc diﬀer-
ences in prevalence of osteoporosis may be age-related.
Indeed, loss of BMD of the lumbar spine occurs at a younger
age than loss of BMD of the hip [6, 20]. In addition, due to
degenerativechangesofthespineathigherage,lumbarBMD
could even be increased in the elderly. In the present trial the
prevalence of osteoporosis was slightly higher using lumbar
spine DXA (27.4%) compared to hip DXA (25.0%), while
the prevalence of osteopenia was clearly higher in the latter
group (33.3% versus 52.4%). Consequently, these patients
may be at risk to develop osteoporosis.
The International Society for Clinical Densitometry
stated that the BMD of the spine and the hip should be
measured and diagnosis of osteoporosis should be based
on the lowest T-score of either the spine or the hip [11].
Indeed, in our COPD patients we found the prevalence
of osteoporosis based on DXA of the hip to be 25%, of
the lumbar spine 27.4%, and of the hip and lumbar spine
combined 38.7% (Table 1). In combination with the fact
that 25% of patients without osteoporosis on whole-body
DXA had osteoporosis on local DXA, it seems reasonable to
advise DXA of the hip and the lumbar spine and diagnose
osteoporosis based on the lowest T-score in COPD patients.
The costs of a whole-body DXA are the same as a local DXA
scan. In addition, the costs of a DXA of the hip or the lumbar
spine only are equal to the costs of a DXA scan of both the
hip and lumbar spine. Therefore, there are no economical
reasons to limit DXA-scan to the hip only. In addition, the
time to make a local DXA scan is less than the time to
make a whole body DXA. More research is needed to assess
risk factors for osteoporosis in COPD in order to determine
which patients should be evaluated for osteoporosis.
The current study showed that the group of patients
without osteoporosis on whole-body DXA but with osteo-
porosis on local DXA consisted of signiﬁcantly more females
than males, patients with a lower six minutes walking
distanceandmorepatientswithGOLDIVandhigherPaCO2
and lower PaO2 levels as compared to patients without
osteoporosis on both whole body- and local DXA (Table 4).
Therefore, in this group of patients, it seems even more
important to use local DXA to determine BMD insteadJournal of Osteoporosis 5
of whole-body DXA. Even more because in the general
population the fracture risk is increased in females [21]
and in COPD patients, a higher prevalence of osteoporosis
has been found in patients with higher GOLD classiﬁcation
and/or hypercapnic patients [22–26]. In the current study,
the increased number of patients with GOLD IV COPD in
group II is probably not due to increased airway obstruction
(FEV1 was not signiﬁcantly diﬀerent in both groups), but to
hypercapnia and/or hypoxemia (Table 4). Indeed, Dimai and
colleagues found a signiﬁcantly lower BMD and increased
serum cross-linked telopeptide of type I collagen (a bone
resorption marker) in hypercapnic patients suggesting that
hypercapnia induces increased bone resorption [23]. With
decreased daily physical activity, hip BMD especially will be
decreased, which will be compensated by the BMD of other
non-weight baring body parts when whole body BMD is
assessed.
When results of whole body DXA-scanning were added
to local DXA-scanning, only 5 extra patients without osteo-
porosis on local DXA had a T-score of < −2.35 on the whole
body DXA-scan (2.4%).
To conclude, in future COPD trials, in which the
diagnosis and/or treatment of osteoporosis is a primary
outcome measure and in daily clinical practice, the most
sensitive procedure for diagnosing osteoporosis should be
used. On the basis of our ﬁndings, we advise to assess the
BMD at the hip and lumbar spine and ﬁnally take the lowest
T-score of these 2 locations to determine the prevalence of
osteoporosis.
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